Long-term response to pazopanib in an elderly man with mRCC. A case report

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has advanced with new drugs.
• Pazopanib, an oral angiogenesis inhibitor, is approved for first-line and post-cytokine mRCC therapy.
• Selecting first-line therapy involves considering trial data, patient history, and drug safety.

Observation:

• A case report of a long-surviving elderly male patient with mRCC is presented.
• The patient did not undergo cytoreductive nephrectomy.
• Treatment with pazopanib was administered.

Findings:

• Pazopanib demonstrated efficacy in an elderly mRCC patient.
• The patient achieved long-term survival.
• Successful management without cytoreductive nephrectomy was observed.

Implications:

• Pazopanib represents a significant therapeutic option for mRCC.
• This case suggests pazopanib's potential in elderly patients and those not undergoing nephrectomy.
• Further research into pazopanib's role in diverse mRCC patient populations is warranted.